Related Articles
IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy